modelUdenafil

Diagram of Udenafil

Extends from Pharmacolibrary.Drugs.ATC.G.G04BE11.

Information

name:Udenafil
ATC code:G04BE11
route:oral
compartments:2
dosage:100mg
volume of distribution:184L
clearance:5.7L/hr
other parameters in model implementation

Udenafil is a phosphodiesterase type 5 (PDE5) inhibitor used primarily for the treatment of erectile dysfunction. It exerts its effect by enhancing the nitric oxide–cGMP pathway, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum. Udenafil is approved for use in several countries, but is not approved by the FDA in the United States.

Pharmacokinetics

Pharmacokinetic parameters obtained from healthy adult male volunteers following single oral administration.

References

  1. Choi, HK, et al., & Shin, JG (2016). The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. Journal of clinical pharmacology 56(11) 1372–1377. DOI:10.1002/jcph.739 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27006150

  2. Shin, KH, et al., & Yu, KS (2010). Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. British journal of clinical pharmacology 69(3) 307–310. DOI:10.1111/j.1365-2125.2009.03601.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20233203

  3. Porst, H, et al., & Sharlip, I (2013). SOP conservative (medical and mechanical) treatment of erectile dysfunction. The journal of sexual medicine 10(1) 130–171. DOI:10.1111/jsm.12023 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23343170

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)